Compound ID | 2168

Update compound information

GSK2556286

Synonym(s): GSK286

Class: Small molecule antibacterial agent

Details of activity: Active against Mycobacterium tuberculosis; ongoing studies to evaluate mode of action but potential cholesterol-dependent mode of action
Propensity to select resistant mutants: Yes
Description: Synthetic novel small molecule; a substituted 4-aryloxypiperidine compound
Institute where first reported: GlaxoSmithKline
Year first mentioned: 2022
Highest developmental phase: Phase 1 (NCT04472897)
Development status: Active (as of 2023)
Chemical structure(s):
Click here for structure editor
Molecular weight: 329.39
Iso. SMILES: CC1=C(C(=CC=C1)OC2CCN(CC2)CC3=CC(=O)NC(=O)N3)C
InChI Key: AZOFJHATIPDIER-UHFFFAOYSA-N
Can. SMILES: CC1=CC=CC(=C1C)OC2CCN(CC2)CC3=CC(=O)NC(=O)N3
InChI: InChI=1S/C18H23N3O3/c1-12-4-3-5-16(13(12)2)24-15-6-8-21(9-7-15)11-14-10-17(22)20-18(23)19-14/h3-5,10,15H,6-9,11H2,1-2H3,(H2,19,20,22,23)
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/45833762
Guide to Pharmacology: GSK2556286
Citation: https://journals.asm.org/doi/10.1128/aac.00132-22

AntibioticDB is supported by GARDP.

If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.